Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference
Rhea-AI Summary
Genelux (NASDAQ: GNLX) announced its participation in the Guggenheim Inaugural Healthcare Innovation Conference in Boston, Massachusetts, from November 11-13, 2024. CEO Thomas Zindrick will engage in a fireside chat on November 11 at 1:30 p.m. ET with Brittany Stopa, Biotech Equity Research Analyst at Guggenheim, discussing clinical-stage programs, recent announcements, and upcoming milestones.
The event will be accessible via webcast, with a replay available for 90 days on the company's IR page. Genelux management will also be available for one-on-one meetings during the conference, with institutional investors invited to register or contact the company directly.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, GNLX declined 3.64%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
WESTLAKE VILLAGE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board, will discuss clinical-stage programs, recent announcements, and upcoming milestones in a fireside chat at the Guggenheim Inaugural Healthcare Innovation Conference, taking place November 11-13, 2024, in Boston, Massachusetts.
The conversation with Brittany Stopa, MD, Biotech Equity Research Analyst at Guggenheim, is scheduled to begin at 1:30 p.m. ET on Monday, November 11, 2024. A webcast link for the Guggenheim Conference event will be available at https://wsw.com/webcast/guggen/gnlx/1958805. An archived replay will be available for approximately 90 days following the event on the company’s IR page.
The Company will also attend one-on-one meetings during the conference. Institutional investors interested in arranging a meeting with Genelux management can register to attend the conference or contact genelux@allelecomms.com.
About Genelux Corporation
Genelux is a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company's most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus. Olvi-Vec currently is being evaluated in OnPrime/GOG-3076, a multi-center, randomized, open-label Phase 3 registrational trial evaluating the efficacy and safety of Olvi-Vec in combination platinum-doublet + bevacizumab compared with physician's choice of chemotherapy and bevacizumab in patients with platinum-resistant/refractory ovarian cancer. The core of Genelux's discovery and development efforts revolves around its’ proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. For more information, please visit www.genelux.com and follow us on Twitter @Genelux_Corp and on LinkedIn.
Investor and Media Contacts
Ankit Bhargava, MD
Allele Communications, LLC
genelux@allelecomms.com
FAQ
When is Genelux (GNLX) presenting at the Guggenheim Healthcare Conference 2024?
How can investors watch Genelux's (GNLX) Guggenheim Conference presentation?
How can institutional investors meet with Genelux (GNLX) management at the Guggenheim Conference?
